Brought to you by 
Biovitrum buys Swedish Orphan for SEK3.5bn in cash and stock
Nov 2009
Executive Summary
Continuing its efforts to transform into solely a specialty pharma company, Sweden's Biovitrum AB will pay SEK3.6bn ($514mm) in cash and stock to buy Swedish Orphan International, a private pan-European company that in-licenses and markets drugs for rare diseases.
Deal Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Full Acquisition
- Includes Earnout
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com